Horizon Therapeutics plc to Participate in Upcoming Conferences

On August 23, 2021 Horizon Therapeutics plc (Nasdaq: HZNP) reported that the Company will participate in the following conferences (Press release, Horizon Therapeutics, AUG 23, 2021, View Source [SID1234586849]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Handelsbanken Life Science Innovation Day 2021 (Virtual)

Date: Wednesday, Aug. 25, 2021
Presentation time: 10 a.m. ET
Morgan Stanley 19th Annual Global Healthcare Conference (Virtual)

Date: Friday, Sept. 10, 2021
Presentation time: 10:15 a.m. ET
The conference presentations will be webcast live and may be accessed by visiting Horizon’s website at View Source A replay of each webcast will be available following the events.

Epigenomics AG: Securities prospectus for the issuance of a mandatory convertible bond in the amount of up to EUR 16.5 million approved by BaFin

On August 23, 2021 Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company" reported that the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, "BaFin") has today approved the securities prospectus required for the issuance of a subordinated mandatory convertible bond in an aggregate principal amount of up to EUR 16,500,000.00 (Press release, Epigenomics, AUG 23, 2021, View Source [SID1234586843]). The mandatory convertible bond may be converted into up to a total of 15,000,000 registered no-par value shares of the Company with a share in the Company’s share capital of up to a total of EUR 15,000,000.00. Accordingly, the conversion price will be EUR 1.10 per share, subject to any anti-dilution adjustments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The mandatory convertible bond consists of up to 165,000 notes with a nominal amount of EUR 100.00 each, which will initially be offered to the existing shareholders of Epigenomics AG by means of a rights offering. Shareholders will also be given the option of over-subscription. The rights offering is published on the Company’s website (View Source) and is expected to be published in the German Federal Gazette on August 26, 2021. The subscription period for the Company’s shareholders is scheduled to start on August 27, 2021, and to end on September 10, 2021 (including each of these two days). Stock exchange trading of the subscription rights on the Hamburg Stock Exchange is also expected to commence at the beginning of the subscription period on August 27, 2021.

The bonds are non-interest bearing (zero coupon) and have a term until September 29, 2027. In addition to the conversion rights of the holders or creditors of the bonds, the terms and conditions of the bonds also include a conversion obligation for all outstanding notes not yet converted at the end of their term.

As announced in the ad hoc announcements of June 11, 2021, and August 20, 2021, Epigenomics AG has entered into a back-stop agreement with its shareholder Deutsche Balaton Aktiengesellschaft, under which the latter has undertaken to acquire all notes in an aggregate principal amount of up to EUR 16,500,000.00 by exercising its subscription rights and by the acquisition of notes not subscribed via subscription rights and oversubscription rights. This obligation expires at the end of the year 2023.

Epigenomics AG plans to use the proceeds from the issuance of the mandatory convertible bond to finance its operations, in particular the further development of the blood-based colorectal cancer screening test Epi proColon Next-Gen. For this purpose, the Company plans to conduct a clinical study in the U.S.A., which is required to obtain approval for the test by the U.S. Food and Drug Administration (FDA). Preparations are currently underway for the clinical trial, which is scheduled to begin in the first half of 2022.

Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China

On August 23, 2021 Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, reported that it has reacquired the exclusive rights to develop and commercialize its all-oral combination product candidate in the People’s Republic of China previously licensed to Shenzhen Salubris Pharmaceuticals Co., Ltd. (Salubris) (Press release, Sunesis, AUG 23, 2021, View Source [SID1234586838]). Pursuant to the mutual termination agreement between Viracta and Salubris, all development and commercialization rights under the license have been returned to Viracta in exchange for a $4.0 million cash payment to Salubris.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We thank the Salubris team for their support of Viracta and their collaborative contributions. As Viracta’s strategic focus remains in precision oncology and Salubris focuses their development efforts on cardiovascular and related disease areas, we agreed the reversion of these rights to Viracta was in the best interest of patients," said Ivor Royston, M.D., President and Chief Executive Officer of Viracta. "China represents an important geographical region for the treatment of patients with EBV-associated cancers. We believe regaining the development and commercial rights in China will enable Viracta to expand our global development strategy and has the potential to unlock significant, long-term and unencumbered value to our shareholders."

Viracta’s combination therapy of nanatinostat, its proprietary investigational drug, and valganciclovir is currently being evaluated in a global Phase 2 pivotal trial for the treatment of patients with Epstein-Barr virus-positive (EBV+) lymphoma. Viracta has also received United States Food and Drug Administration clearance of an Investigational New Drug application to proceed into a global Phase 1b/2 trial evaluating its combination therapy in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Initiation of this Phase 1b/2 trial is expected in the second half of 2021.

About Nanatinostat

Nanatinostat (VRx-3996) is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta. Nanatinostat is selective for specific isoforms of Class I HDACs, which is key to inducing viral genes that are epigenetically silenced in EBV-associated malignancies. The nanatinostat and valganciclovir combination is being investigated in various subtypes of relapsed/refractory EBV+ lymphoma in multiple clinical trials, including a registration-enabling global, multicenter, open-label basket trial.

Emergent BioSolutions to Participate in Investor Conferences

On August 23, 2021 Emergent BioSolutions Inc. (NYSE: EBS) repored that members of the company’s senior management team will participate in the following investor conferences (Press release, Emergent BioSolutions, AUG 23, 2021, View Source [SID1234586836]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Three Part Advisors IDEAS Midwest Conference
August 25-26, 2021
Pre-recorded presentation available on August 26; 1-on-1 meetings on August 26
Wells Fargo 2021 Virtual Healthcare Conference
September 9-10, 2021
Fireside chat on September 9 at 9:20 am ET; 1-on-1 meetings all day
Morgan Stanley 19th Annual Global Healthcare Conference
September 9-10 & 13-15, 2021
Fireside chat on September 9 at 3:30 pm ET; 1-on-1 meetings all day
Baird’s 2021 Global Healthcare Conference
September 14-15, 2021
Fireside chat on September 14 at 4:55 pm ET; 1-on-1 meetings all day
Singular Research Compelling Values Webinar
September 16, 2021
Company presentation schedule will be posted on website
Cantor 2021 Virtual Global Healthcare Conference
September 27-30, 2021
Fireside chat on September 27 at 4:00 pm ET; 1-on-1 meetings all day
For conferences where a presentation is planned, the company’s webcast presentation may include a discussion of the company’s recent business developments as well as its financial results and guidance. The webcast will be available both live, if possible, and by replay, and will be accessible from the Emergent website.

Ana Patricia Gámez Joins Cancer Research Institute in the Movement for Racial Health Equity, Named Moderator of First Spanish-Language Virtual Cancer Immunotherapy Summit

On August 23, 2021 The Cancer Research Institute (CRI), a nonprofit organization spearheading transformative research to harness the immune system’s power to control and potentially cure all cancers, reported that it will offer its first-ever Virtual Cancer Immunotherapy Summit in Spanish on September 16, 2021, 2-5 p.m. ET (Press release, Cancer Research Institute, AUG 23, 2021, View Source [SID1234586835]). This free interactive online event, moderated by TV personality, podcast host, and former national Univision & Unimas TV host, Ana Patricia Gámez, will connect cancer patients and caregivers with revolutionary research updates from leading immunotherapy experts driving scientific discovery and advancement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to the Center for Disease Control (CDC), cancer is the leading cause of death among Hispanic people, with current cancer research and statistics indicating lung, breast, and colorectal cancer having the greatest impact in this community. Studies show that lung cancer is the leading cause of cancer death among U.S. Hispanic men and the second leading cause of cancer death among U.S. Hispanic women. Breast cancer is the leading cause of death in Hispanic females and colorectal cancer is the third leading cause of cancer death among both Hispanic men and women.

In fact, research indicates that one in three U.S. Hispanic people (both women and men alike) will be diagnosed with cancer in their lifetime. This urgent public health crisis has propelled the Cancer Research Institute to lead the charge in bringing the promise of immunotherapy to this underserved community with in-language information, research updates, and clinical trial access. Cancer immunotherapy is a form of cancer treatment that uses the body’s own immune system to control and eliminate cancer.

"I’ve dedicated my career to the research and development of immunotherapy as an effective cancer treatment. Sharing information in Spanish about this revolutionary treatment option with U.S. Hispanic patients is urgently needed and allows me the opportunity to positively impact the lives of this community as well as support the Cancer Research Institute’s efforts for racial health equity," said Antoni Ribas, M.D., Ph.D., member of the CRI Scientific Advisory Council, director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, and the chair of the Melanoma Committee at SWOG Cancer Research Network.

"Working with leaders in the immunotherapy field and leveraging the reach of our partners such as Univision and Ana Patricia Gámez, we hope to engage with U.S. Hispanic cancer patients, survivors, caregivers, and support systems to positively impact the health, wellbeing, and overall cancer outcomes for the U.S. Hispanic community," said Jill O’Donnell-Tormey, Ph.D., CEO and director of scientific affairs at CRI. "Hispanic people are underrepresented when it comes to accessing quality cancer care. The number of patients getting the best treatment isn’t proportional to the number of people who need that treatment. The lack of diversity in cancer clinical trials, too, is a major issue that slows discovery, so CRI is committed to helping solve this problem by connecting U.S. Hispanic patients with leading physician-scientists who want just one thing—to cure cancer."

"It’s my honor to serve as the moderator for the first-ever CRI Virtual Cancer Immunotherapy Summit in Spanish," said Ana Patricia Gámez. "My connection to cancer is personal and real—I lost my father much too soon and that changed my life forever. It is my privilege to help Hispanic cancer patients and caregivers in their healthcare journey. This event gives me the chance to do my part to provide these mothers, fathers, and family members with access to the latest information on cancer treatments and clinical trials."

From the comfort and safety of home, attendees of the first-ever free CRI Virtual Cancer Immunotherapy Summit in Spanish can expect to:

Learn about immunotherapy and how it helps patients, caregivers, and their families
Hear from leading physician-scientists with expertise in cancer immunotherapy as well as patients treated with immunotherapy
Gain valuable insight into how clinical trials work to understand whether they are a good option for cancer patients or a loved one and how to find one
Discover issues specific to the Hispanic and Latino communities in the United States regarding cancer care and how doctors, organizations, advocates, and individuals are addressing these challenges
Support for the Spanish-language 2021 CRI Virtual Cancer Immunotherapy Summit is generously provided by the following sponsors:

Univision, official media sponsor
Bristol Myers Squibb, Merck (also know as MSD outside the U.S.), Lily Oncology and Alkermes Inspiration Grant
This summit comes on the heels of the launch of the first-ever Spanish-language cancer immunotherapy information hub to connect Hispanic patients and caregivers with the latest research and treatment options. The Cancer Research Institute is committed to closing the information and research gap to better serve the Hispanic community in the United States. Visit cancerresearch.org/es to see the robust and helpful offering of information now available in Spanish. Visit cancerresearch.org/es/conferencia to register for the Spanish-language 2021 CRI Virtual Cancer Immunotherapy Summit.